CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

CHEPLAPHARM places additional € 300 million capital market loan in London with Institutional Investors

Following a successful roadshow with Institutional Investors in London, CHEPLAPHARM Arzneimittel GmbH was able to issue another loan (TLB market) in mid-November.

This will provide the company with the liquid funds to consistently pursue its sustainable M&A strategy

“Just in the months of August and September, "said Cheplapharm CEO Sebastian F. Braun," we closed another five acquisitions and are planning one last deal later this year. This will help to further diversify our product portfolio. The new financing options put us in a position to vigorously pursue our growth strategy.“

Prerequisites for the second, successful coup on the London capital market were external ratings by S&P and Moody's and the support of an international banking group.

Commenting on the successful mission in London, Jens Rothstein, CFO, said: "We are very pleased with the continued demand and investor confidence in the Cheplapharm business model and our growth strategy. Thanks to the new credit facilities at very attractive rates, we now have the necessary flexibility and liquidity to further develop the company."

Contact Investor Relations:
CHEPLAPHARM Arzneimittel GmbH | Jens Remmers | Ziegelhof 24 | 17489 Greifswald | investor-relations(at)cheplapharm.com


Investor Relations topics

Back to top expand_less